Cost-effectiveness analysis of chemotherapy and chemotherapy combined with immunotherapy in the treatment of small cell lung cancer
Objective Cost-effectiveness analysis was used to evaluate the economics of three regimens in the treatment of small cell lung cancer:chemotherapy(etoposide combined with carboplatin/cisplatin),chemotherapy combined with PD-LI(atezolizumab/durvalumab)and chemotherapy combined with PD-1(serplulimab).Methods The medical records of 94 patients with small cell lung cancer admitted to Shandong Provincial Hospital from January 2020 to April 2023 were retrospec-tively analyzed and divided into three groups according to the treatment regimen.The clinical efficacy of the three groups after four cycles of treatment was evaluated,adverse effects were recorded,and cost-effectiveness analysis was performed.Results The objective response rates of the three groups were:chemotherapy group 56.25％,chemotherapy combined with PD-L1 group 63.33％,chemotherapy combined with PD-1 group 62.50％,the difference was not statistically significant(P＞0.05).There was no significant difference in the incidence of leukopenia,thrombocytopenia and abnormal liver function among the three groups(P＞0.05),and the incidence of gastrointestinal adverse reactions was 41.66％in the chemotherapy group,40.00％in the chemotherapy combined with PD-L1 group,and 6.25％in the chemotherapy combined with PD-1 group,the difference was statistically significant(P＜0.05).The objective response rate was used as the clinical efficacy index,and the cost-effectiveness ratios of the three groups were 480.88,2 026.80 and 1 001.47,respectively.The incremental cost-effectiveness ra-tios of chemotherapy combined with PD-L1 group and chemotherapy combined with PD-1 group were 14 309.06 and 5 686.81,respectively.The conclusion of sensitivity analysis is consistent with that of cost-effectiveness analysis.Conclusion In the first-line treatment of extensive-stage small cell lung cancer,the ORR of chemotherapy alone was similar to that of combined immunization regimen,and the cost-effectiveness ratio of chemotherapy group was the best.
Small cell lung cancerChemotherapyProgrammed cell death-1Programmed death-ligand 1Cost-effec-tiveness analysis
万方数据
维普
